New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2012
09:20 EDTFCX, CNVO, QCOR, RIG, TSLAPre-market top 5 gainers
The following stocks were the top percentage gainers before the open on solid volume of at least 50,000 shares, trading at over $10. CNVO 48%, TSLA 14%, QCOR 5.2%, FCX 2.3%, RIG 2%.
News For CNVO;TSLA;QCOR;FCX;RIG From The Last 14 Days
Check below for free stories on CNVO;TSLA;QCOR;FCX;RIG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 7, 2014
11:05 EDTQCOR High option volume stocks: EXC QCOR SQQQ GNK PPG
Subscribe for More Information
10:40 EDTQCORShort-seller target Questcor spikes after deal to be bought by Mallinckrodt
Questcor (QCOR) shares are sharply higher this morning after the company agreed to be bought by Mallinckrodt (MNK) in a transaction valued at approximately $5.6B. WHAT'S NEW: Questcor, a biopharmaceutical company whose primary drug, H.P. Acthar Gel, is approved by the FDA for the treatment of 19 indications, will be acquired by Mallinckrodt for about $5.6B, made up of $30.00 per share in cash and 0.897 Mallinckrodt shares for each Questcor share they own. The total consideration equated to approximately $86.10 per Questcor share based on the closing price of Mallinckrodt shares on April 4. After the deal closes, Mallinckrodt shareholders will own approximately 50.5% and former Questcor shareholders will own approximately 49.5% of the combined company's stock. The deal is expected to immediately add to Mallinckrodt's fiscal 2014 adjusted earnings per share and significantly add to fiscal 2015 adjusted EPS. The transaction is targeted to close in the third quarter. On the companies' conference call discussing the merger, Questcor said it believes that its first quarter sales will be "somewhat lower" than the fourth quarter of 2013, but also "substantially higher" than last year's first quarter; the consensus estimate for Q1 revenue is $242.08M. Questcor also said that it sees a "favorable" tax structure and operating cash flow, as well as immediate value for shareholders. Mallinckrodt said sees about a 10% decline in the tax rate with the Questcor deal and believes it will realize immediate tax benefits. Mallinckrodt added that its focus will be on deleveraging in the coming months to allow for strategic acquisitions. WHAT'S NOTABLE: Of the 19 indications approved for Acthar, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. Questcor has been a frequent target of the short-selling blog Citron Research in the past. As recently as March 14, Citron Research claimed Questcor was "deceiving" the FDA and investors, alleging H.P. Acthar Gel's active ingredient is less than 20% of the label specification. PRICE ACTION: Questcor is trading up $11.48, or 16.91%, to $79.35 in mid-morning trading. Meanwhile, Mallinckrodt is down $1.70, or 2.72%, to $60.82.
10:00 EDTQCORQuestcor rises 21.2%
Subscribe for More Information
09:34 EDTTSLAActive equity options trading on open
Subscribe for More Information
09:10 EDTQCOROn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:00 EDTQCORQuestcor rises 29.2%
Subscribe for More Information
07:46 EDTTSLATesla potential weak results priced into shares, says RW Baird
Subscribe for More Information
07:16 EDTQCORMallinckrodt and Questcor hold a joint conference call
Subscribe for More Information
07:08 EDTQCORQuestcor to be bought by Mallinckrodt for cash, stock valued at $86.10 per share
Subscribe for More Information
07:04 EDTQCORQuestcor acquired by Mallinckrodt for $5.6B
Subscribe for More Information
April 4, 2014
18:47 EDTTSLATesla to get fewer eco credits from California, Bloomberg says
Subscribe for More Information
16:00 EDTTSLAOptions Update; April 4, 2014
iPath S&P 500 VIX Short-Term Futures up 89c to 41.88. Option volume leaders: AAPL C P NFLX LNG BAC INTC TSLA TWTR according to Track Data.
12:14 EDTTSLATesla breaks nascent uptrend, levels to watch
Subscribe for More Information
09:36 EDTTSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA MU GNK AMZN FB GILD MA NFLX
April 3, 2014
16:00 EDTTSLAOptions Update; April 3, 2014
Subscribe for More Information
10:00 EDTFCXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:37 EDTTSLAActive equity options trading on open
Subscribe for More Information
09:18 EDTFCXFreeport McMoRan upgraded at Macquarie
Subscribe for More Information
08:30 EDTFCXFreeport McMoRan upgraded to Outperform from Neutral at Macquarie
Subscribe for More Information
07:47 EDTTSLATesla suing NJ over being 'unfairly targeted' by new rules, AP says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use